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Abstract: Glioblastoma (GBM), the most commonly occurring primary tumor arising within the
central nervous system, is characterized by high invasiveness and poor prognosis. In spite of the
improvement in surgical techniques, along with the administration of chemo- and radiation therapy
and the incessant investigation in search of prospective therapeutic targets, the local recurrence
that frequently occurs within the peritumoral brain tissue makes GBM the most malignant and
terminal type of astrocytoma. In the current study, we investigated both GBM and peritumoral
tissues obtained from 55 hospitalized patients and the expression of three molecules involved in
the onset of resistance/unresponsiveness to chemotherapy: O6-methylguanine methyltransferase
(MGMT), breast cancer resistance protein (BCRP1), and A2B5. We propose that the expression
of these molecules in the peritumoral tissue might be crucial to promoting the development of
early tumorigenic events in the tissue surrounding GBM as well as responsible for the recurrence
originating in this apparently normal area and, accordingly, for the resistance to treatment with
the standard chemotherapeutic regimen. Notably, the inverse correlation found between MGMT
expression in peritumoral tissue and patients’ survival suggests a prognostic role for this protein.
Keywords: glioblastoma; peritumoral area; MGMT; BCRP1; A2B5; chemotherapy; cancer stem cells
1. Introduction
Glioblastoma (GBM) is a grade IV tumor of the central nervous system (frequently
referred to as a grade IV astrocytoma). GBM is the most common and malignant intracra-
nial tumor in adults [1]. Current treatment choices for GBM at diagnosis are limited, and
standard treatment consists of maximal surgical resection, followed by concurrent radiation
therapy and chemotherapy [2]. Despite the massive surgical resection, GBM preserves high
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invasiveness with frequent recurrence, allegedly due to infiltrating tumor cells remaining
in the adjacent brain tissues, leading to poor prognosis characterized by a median overall
survival ranging from 12 to 15 months [3]. Progress has been made in the development of
prognostic tools, identifying molecular markers that help predict survival and conceive
individualized therapy regimens, improving the response rate [4]. However, promising
approaches aimed at targeting primary and recurrent GBM, such as immunotherapies,
receptor tyrosine kinase inhibitors, targeted toxins, and anti-angiogenic drugs, resulted in
unsatisfactory outcomes [5]. Notably, due to its involvement in the progression and recur-
rence of GBM, the peritumoral (PT) tissue is emerging as a remarkable field of investigation
in this area. Our previous studies have focused on the potential role of the GBM PT tissue
in recurrence, taking into account the tissue surrounding the enhanced lesion up to 3.5 cm
from the tumor margin [6–11]. Within the GBM neighboring tissue, the presence of reactive
astrocytes and microglia [8–12], abnormal gene expression [10–13], and altered tumor-like
neovascularization were assessed [9]. Evidence has suggested the presence of a subpopula-
tion of cells endowed with a cancer-stem-like cell (CSC) phenotype [7–9,11,14] residing in
the PT tissue that may be responsible for the occurrence of pre-/pro-tumorigenic events
and for the resistance to chemo- and radiotherapy [15,16]. GBM recurrence in the PT area
has been observed approximately in 90% of patients and appears to be tightly correlated
with the resistance to the standard temozolomide (TMZ) chemotherapy [17]. TMZ is an
alkylating agent that modifies DNA by introducing methyl groups at the N7 position of
guanine, the O3 position of adenosine, and the O6 position of guanosine, leading to DNA
breaks and subsequent apoptosis of tumor cells [18]. Overexpression of the dealkylating en-
zyme O6-methylguanine methyltransferase (MGMT), which removes the cytotoxic methyl
groups from the O6 position, has been suggested to play a crucial role in the development
of TMZ resistance as well as a major cause of standard therapy failure [19,20]. Methylation
of specific promoter sites in the MGMT promoter decreases protein expression, making
promoter methylation status a predictive biomarker in response to TMZ [20]. Failure of
both conventional and targeted therapy can also occur through an active efflux of drugs,
leading to their decreased intracellular levels. Drug insensitivity consequently develops,
usually to various agents. One of the well-defined sources of this cancer cell multi-drug
resistance (MDR) is the increased expression of ATP binding cassette (ABC) transporters,
which extrude chemically unrelated drugs out of the cell [21]. Among them, breast cancer
resistance protein (BCRP1), also known as ABCG2, one of 48 human transporters of the
ABC family, is found in normal brain tissue at the blood–brain barrier, where it likewise
plays a protective function against potentially damaging compounds [22]. It has been
demonstrated that efflux transport in the blood–brain barrier is involved in limiting the
brain distribution of palbociclib, with critical implications for determining effective dosing
regimens of palbociclib therapy in the treatment of brain tumors [23]. Moreover, it has been
demonstrated that BCRP1 function not only correlates with high stem cell (SC) marker
expression and self-renewal capacity but can also actively drive these SC features in some
GBM cultures without regulating glioma cell tumorigenicity or radiation resistance [24].
The strong TMZ resistance of CD133+ CSCs obtained from GBM patients is probably
contributed by the CD133+ cells displaying high BCRP1 and MGMT levels [25]. Several
gangliosides, including GD2 and GD3, have been identified as GBM CSC markers playing
a key role in GBM tumorigenesis and are now being considered attractive therapeutic
targets [26,27]. Notably, it was recently demonstrated that anti-GD2 monoclonal antibody
immunotherapy significantly increased TMZ toxicity in cultured GBM cells by enhancing
TMZ uptake and prevented the extension of the TMZ-resistant CSC pool within the tumor
bulk in vivo [28]. The A2B5 epitope belongs to the sialoganglioside family and is expressed
by GBM CSCs displaying a high proliferation rate and strong migratory/invasive capacity
and able to originate tumors in nude mice independently of CD133 expression [29]. A2B5
is thought to be a marker of poor prognosis, and low-grade A2B5+ astrocytomas may
have a higher rate of recurrence than the tumors of A2B5- lineage [30]. In this study,
a comparative immunohistochemical analysis of the expression of MGMT, BCRP1, and
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A2B5 was performed on paraffin-embedded tissue sections obtained from GBM and PT
parenchyma of 55 patients diagnosed with primary supratentorial GBM who underwent en
bloc surgery. The resulting PT profile was compared with that of the GBM zone to identify
characteristics specific to the PT zone and its correlation with clinical parameters.
2. Results
2.1. Immunohistochemical Analysis of MGMT, BCRP1, and A2B5 in GBM and PT Tissue
The expression of MGMT, BCRP1, and A2B5 was analyzed by immunohistochemistry,
both in GBM and in PT tissue obtained by surgery. Immunoreactivity of the three molecules
was found in both GBM- and PT-tissue-derived sections (Figure 1). Due to the great histo-
logical complexity of the tumor and the PT tissue, we performed an unbiased stereometric
analysis of histological samples by evaluating the cell density of both positive and negative
cells for MGMT, BCRP1, and A2B5, as described in the Materials and Methods section.
This analysis clearly showed a higher cell density in GBM than in PT tissue (Figure 1).
As regards MGMT expression in GBM samples, it turned out to be mainly localized in the
nuclei of endothelial cells (ECs) of the neo-vasculature (Figure 1A). Yet, we did not detect
MGMT expression in malignant cells (i.e., cells with atypical nuclei). In PT tissue, MGMT
was highly expressed both in ECs and all around the vessel wall (Figure 1B). The results
of the stereometric analysis clearly showed that the cell density of MGMT-negative cells
was higher in tumor samples compared to the PT area (p < 0.0001, two-sample Wilcoxon
rank-sum, Mann–Whitney test; PT: median, 52.1; range, 0.54–92.4; GBM: median, 10.2;
range, 0.0–76.5) (Figure 2A). Immunohistochemical analysis of BCRP1 indicated that the
molecule was expressed in the plasma membrane and within the cytoplasm both in GBM
and in PT tissue (Figure 1C,D). In addition, stereometric analysis performed on histological
samples indicated a significantly higher BCRP1-positive cell density in PT tissue than
in GBM (p < 0.02; PT: median, 18.1; range, 0.4–95.6; GBM: median, 6.9; range, 0.0–72.1)
(Figure 3A,B). As it concerns the expression of A2B5, immunohistological analysis revealed
that both in GBM and in PT tissue, the ganglioside was located on the cell surface and
within the cytoplasm (Figure 1E,F). In addition, A2B5 immunoreactivity was found in
ECs and in other cell types in the surrounding tissue. However, there was no statistically
significant difference in A2B5 expression between PT tissue and GBM (p = 0.69; PT: median,
28.4; range, 0.0–98.4; GBM: median, 17.3; range, 0.0–96.8) (Figure 4A,B).




Figure 1. Immunohistochemistry analysis of glioblastoma (GBM) and peritumoral (PT) areas of 
surgical samples. Primary tumor specimens and adjacent brain tissue were collected, fixed in 10% 
formalin, and analyzed by means of immunohistochemistry. Arrowheads indicate the immunore-
activity of O6-methylguanine methyltransferase (MGMT), breast cancer resistance protein 
(BCRP1), and A2B5 in both areas. (A, C, and E) MGMT, BCRP1, and A2B5 expression in GBM 
samples; (B, D, and F) MGMT, BCRP1, and A2B5 expression in PT tissue. 
 
Figure 2. Stereological analysis of MGMT expression in both GBM and PT areas. Histological sam-
ples subjected to immunohistochemistry analysis were further evaluated by stereological analysis. 
The number of both labeled and unlabeled cells was employed to quantify the expression of 
MGMT in both GBM and PT tissue, as specified in the Materials and Methods section. (A) Red and 
blue bars show the number of MGMT-positive and MGMT-negative cells/mm2, respectively. The 
data are presented as the mean ± standard error (SE). (B) Plots show the percentage of MGMT-
positive cells in GBM and PT areas. N = 50; the horizontal line represents the median value; p indi-
cates the result of the Mann-Whitney test. 
Figure 1. Immunohistochemistry analysis of glioblastoma (GBM) and peritumoral (PT) areas of
surgical samples. Primary t mor specimens and adjacent brain tissue were collected, fixed in 10% for-
malin, and analyzed by me ns of immunohistochemistry. Arrowheads indicate the immunoreactivity
of O6-methylguanine methyltransferase (MGMT), breast cancer resistance protein (BCRP1), and
A2B5 in both areas. (A,C,E) MGMT, BCRP1, and A2B5 expression in GBM samples; (B,D,F) MGMT,
BCRP1, and A2B5 expression in PT tissue.
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Figure 3. Stereological analysis of BCRP1 expression in both GBM and PT areas. Immunohisto-
chemistry results were further evaluated by subjecting histological slides to an unbiased stereolog-
ical analysis. Both BCRP1-labeled and unlabeled cells were counted, and the cell density of BCRP1 
was graphed. (A) Red and blue bars show the number of BCRP1 cells/mm2. The data are presented 
as the mean ± SE. (B) Plots show the percentage of positive cells in GBM and PT areas. N = 50; the 
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Figure 4. Stereological analysis of A2B5 expression in both GBM and PT areas. To more accurately 
evaluate the immunohistochemistry results, an unbiased stereological technique was used. Within 
each selected region of interest (ROI), the number of both immunopositive and immunonegative 
cells were used to estimate the expression density of A2B5 in the indicated histological areas. (A) 
Red and blue bars show the number of A2B5-positive and A2B5-negative cells/mm2, respectively. 
The data are presented as the mean ± SE. (B) Plots show the percentage of A2B5-positive cells in 
GBM and PT areas. N = 50; the horizontal line represents the median value; p indicates the result of 
the Mann-Whitney test. 
2.2. Survival Analysis of GBM Patients 
The correlation of MGMT, BCRP1, and A2B5 expression with prognosis of glioma 
patients was investigated through Kaplan–Meier survival curve analysis with a log-rank 
test of 50 GBM patients (Table 1, Figure 5). To determine the prognostic value of MGMT, 
BCRP1, and A2B5 in GBM patients, univariate Cox regression analysis was employed. 
Remarkably, only high MGMT expression in the PT area correlated with a high-risk factor 
for GBM patients (p < 0.05; z = −2.12; 95% confidence interval 0.026–0.00095). According to 
the Cox model (proportional hazard, Cox regression: Breslow method for ties), the varia-
ble significantly correlated with survival was the PT histochemical group, which has a 
Figure 3. Stereological analysis of BCRP1 expression in both GBM and PT areas. Immunohistochemistry results were further
evaluated by subjecting histological slides to an unbiased stereological analysis. Both BCRP1- abel d and unlabel cells
were counted, and the cell density of BCRP1 was graphed. (A) Red and b ue bar show the umber of BCRP1 cells/mm2.
The data are presented as the mean ± SE. (B) Plots show the percentage of positive cells in GBM and PT areas. N = 50; the
horizontal line represents the median value; p indicates the result of the Mann-Whitney test.
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2.2. Survival Analysis of GBM Patients
The correl tion MGMT, BCRP1, and A2B5 expression with prognosis of glioma
patients was investigated through Kaplan–Meier survival curve analysis with a log-rank
test of 50 GBM patients (Table 1, Figure 5). To determine the prognostic value of MGMT,
BCRP1, and A2B5 in GBM patients, univariate Cox regression analysis was employed.
Remarkably, only high MGMT expression in the PT area correlated with a high-risk factor
for GBM patients (p < 0.05; z = −2.12; 95% confidence interval 0.026–0.00095). According to
the Cox model (proportional hazard, Cox regression: Breslow method for ties), the variable
significantly correlated with survival was the PT histochemical group, which has a negative
z value to indicate that its expression is inversely correlated with survival (Figure 5). The
ROC curve did not identify any cutoff that can be used to define positive or negative
samples. In addition, based on our statistical analysis, it is conceivable that the decrease
in the average age of the patients (<59 years) as well as in MGMT expression (<50%)
would increase the survival time of some of the subjects analyzed without any significant
gender difference, although over 60% of them would have died within 20 months from
histochemical diagnosis. Moreover, with an increase >50% of MGMT expression and
an average age < 59 years, 50% of the patients survived after 30 months from diagnosis.
Therefore, the only parameter that significantly correlated with survival was the age.
Patients ≤ 64 years old at diagnosis had a better median survival time compared with
patients diagnosed at ≥65 years of age (14 and 12 months, respectively; p = 0.028 log-
rank test).
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Table 1. Clinicopathological characteristics of 55 patients with primary GBM
Variable Total


















Survival time (months) Median 13
Range 0–59
Clinical outcome DOD 50
DOOC 5
Abbreviations: KPS, Karnofsky performance status; DOD, dead of disease; DOOC, dead of other causes; NA,
not assessed.
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Figure 5. Survival of GBM patients is inversely correlated to MGMT expression in the PT area: The
Kaplan–Meier plot depicts the differences in survival when patients with a percentage of MGMT-
positive cells >50% were stratified based on the tissue areas (GBM, tumoral area; PT, peritumoral
area). Furthermore, the number of surviving subjects per time unit is described in Table of Subjects at
Risk. According to the Cox model (proportional hazard, Cox regression: Breslow method for ties),
survival decreases significantly for patients showing >50% of MGMT-positive cells in the PT area
(p < 0.05 log-rank test; z = −2.12; 95% CI = 0.026–0.00095).
Int. J. Mol. Sci. 2021, 22, 1620 7 of 13
3. Discussion
GBM is among the deadliest of gliomas, characterized by high heterogeneity and ele-
vated resistance to treatment with TMZ, a cytotoxic drug employed to block proliferation
of tumor cells. A number of studies have suggested that both intrinsic and acquired TMZ
resistance are related to the expression level of DNA alkylating proteins and DNA repair
enzymes [19,20]. Molecular subtyping of GBM tissue has shown promise in recognizing
subsets of patients who may be uniquely responsive to specific adjuvant therapeutic ap-
proaches [31]. Indeed, aggressive surgery and standard multimodal adjuvant treatments
fail to prevent local recurrence that invariably appears within the surrounding brain tis-
sue [32]. Therefore, there is an urgent need to deepen our understanding of the histological
and molecular features of the seemingly normal PT tissue to investigate the mechanisms
responsible for the onset of relapses, tumor progression, and treatment failure in GBM
patients. In GBM, promoter methylation of the gene encoding MGMT is the molecular
fingerprint with the highest clinical impact. The MGMT gene codes for a ubiquitously
expressed nuclear DNA repair protein participating in cellular defense against mutage-
nesis and toxicity due to alkylating agents such as TMZ [33]. The intracellular level of
MGMT has been predicted to correlate with chemoresistance. The methylation status of
the MGMT promoter is, to date, considered of high clinical interest and represents a master
mechanism accountable for chemoresistance, although the occurrence of an abnormal
DNA repair system and multi-drug resistance contribute to this scenario [34]. Randomized
trials of newly diagnosed GBM patients treated with TMZ have revealed that MGMT
gene silencing by promoter hypermethylation correlates with improved survival. On the
other hand, GBM patients with an unmethylated MGMT promoter, leading to high MGMT
protein expression, show poorer outcomes and a negligible response to TMZ [3,7]. Notably,
in these latter GBM patients, various microRNAs (miR-142-3p, miR-181d, miR-221/222,
miR-370-3p, and miR-603) acting as epigenetic negative regulators of MGMT expression
and/or functionality are able to increase sensitivity to TMZ in vitro as well as in vivo [35].
In this study, we found a significantly higher percentage of cells showing positive staining
with the antibody to MGMT in PT tissue than in GBM, independently from the presence
of tumor cells in the former area. In addition, in both GBM and PT, MGMT expression
was not detected in malignant cells, and in PT tissue the enzyme was clearly expressed
in ECs of the neo-vasculature and around the vessel wall. These findings are in line with
immunohistochemical data obtained from a medulloblastoma study where adjacent normal
PT cerebellar tissue did not show immunoreactivity for MGMT, while ECs of this area were
decorated by the antibody [36]. The role of MGMT in modulating GBM-induced angiogene-
sis and response to anti-angiogenic drugs has been also established [37]. Indeed, it has been
demonstrated that GBM cells stably transfected with MGMT have a decreased capability to
induce tube formation in vitro and tumorigenicity in vivo compared to mock transfected
cells. The possible confirmation of these results in vivo could involve the evaluation of
the expression levels of MGMT as a discriminant for selecting patients who may respond
to anti-angiogenic therapy. In our study, unlike ECs, no tumor cells in GBM or PT tissue
were stained for MGMT. In this setting, the shift toward the described anti-angiogenic
profile would not occur. Indeed, we found that a higher percentage of MGMT-positive
cells in the PT area correlates with poorer patient survival. Our findings suggest that an
MGMT-positive endothelium and the perivascular niche of the PT vessels may provide a
protective environment against TMZ. This seems to be already established in GBM tissue.
Evidence has actually suggested that GBM-associated ECs and the perivascular niche make
a significant contribution to TMZ resistance [38,39]. In vitro studies have demonstrated
that although TMZ is highly cytotoxic to the MGMT-negative GBM cell line U87MG, it
does not affect the cell viability, proliferation rate, or migration of GBM-associated ECs [40].
Likewise, data obtained from an in vivo mouse intracranial GBM model indicated no
significant effects induced by TMZ on microvessel density. Overexpression of the CSC-
associated functional markers of the superfamily of ABC transporters represents one of
the main mechanisms of drug resistance in the brain, leading to poor drug delivery to
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tumor cells [21]. Just as for MGMT expression, we found a higher percentage of cells
positively stained for the ABC transporter BCRP1 in PT tissue with respect to GBM sam-
ples. This finding is in line with recently reported evidence concerning the expression of
another member of the superfamily of the ABC transporters, ABCC3, in human glioma
samples. The expression level of ABCC3 in glioma tissues was significantly lower than
that in normal brain tissues [29]. Although ABCC3 function has not yet been elucidated, its
downregulation has been found to be linked to patients’ overall survival and disease-free
survival rates [29]. This makes it conceivable for the ABCC3 gene to play a prognostic role.
As for A2B5, it has been found that the expression level of this ganglioside in different
glioma cell lines positively correlates with cell proliferation, migration, clonogenicity, and
tumorigenicity [41]. The A2B5-positive cell fraction isolated from GBM was reported to
display morphological and functional features typical of brain-tumor-initiating cells in
terms of the ability to migrate, proliferate, and differentiate into oligodendroglial and type-
1/type-2 astroglial cells [42], while A2B5-negative cell fraction was able to form tumors
when injected into nude mice [43]. Just as for MGMT and BCRP1 expression, we found a
higher density of cells showing immunopositive staining for A2B5 in the tissue adjacent to
GBM with respect to the malignant lesion. The presence of cells with stem-like cell features
in the tissue surrounding GBM has already been established. We previously reported the
expression of the progenitor/stem cell marker GD3 ganglioside in GBM, PT tissue, and
CSCs, isolated from the tumor and PT areas [11]. We found GD3 expression in PT tissue
up to a remarkable distance of 3.5 cm from the tumor margin, despite the absence of cells
with morphological features of malignant transformation. Moreover, we have shown GD3
expression in ECs of both tumor and PT tissue, suggesting that this ganglioside is also
involved in neoangiogenesis. Indeed, gangliosides have been found to induce both VEGF
secretion by GBM cells [44] and EC migration [45]. In our previous studies, the expression
of phosphorylated extracellular signal-regulated kinases 1/2 (pERK1/2), phosphorylated
c-Jun NH2-terminal kinases (pJNK), other stem cell markers (such as Nestin, CD133, and
NG2 proteoglycan), as well as angiogenesis-related factors (CD105, VEGF, VEGFR1/2,
HIF-1α, and HIF-2α), has been demonstrated in GBM and PT tissue, even in the absence
of frankly neoplastic cells [7–9,11,46,47]. Moreover, genome-wide expression profiles of
samples isolated from the GBM tumor mass and apparently healthy white matter adjacent
to the tumor revealed various dysregulated genes in this latter area [10]. Thus, the results
of the current study enrich a growing body of knowledge testifying to the occurrence of
early tumorigenic events in the tissue surrounding GBM. Also, we cannot exclude that the
existence of CSCs in such an altered microenvironment might be responsible for tumor
recurrence as well as for resistance to standard therapy. In conclusion, we believe that
the detection of high levels of the three above-mentioned molecules, engaged in DNA
repair and drug efflux in the apparently healthy GBM neighboring tissue, may represent
a first line of resistance to treatment with the standard chemotherapeutic regimen. More-
over, the inverse correlation found between MGMT expression in PT tissue and patients’
survival suggests a prognostic role for the immunodetection of this protein in the GBM
neighboring tissue.
To better elucidate the significance of these data, further coexpression analysis of
markers of stemness and differentiation would be important to define the single-cell-type
relationship with tumor progression and response to therapy.
4. Materials and Methods
4.1. Patients and Tissue Samples
Primary tumor specimens and adjacent brain tissue were obtained from 55 patients di-
agnosed with primary supratentorial GBM who underwent en bloc surgery at the Institute
of Neurosurgery of the Catholic University of the Sacred Heart, Rome, Italy. Neuronav-
igation and intraoperative ultrasound were used to define and maximize the extent of
intracranial tumor resection. The tumor and neighboring apparently normal tissue were re-
moved en bloc. The surgical specimens were cut and opened in a bookwise fashion. Using
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this technique, the difference between the tumor border and its surrounding apparently
normal white matter was evident and the distance from the white matter adjacent to the
tumor edge and this latter was well defined and measured [48]. In each patient, complete
removal of the enhanced lesion (T1-weighted zone) and extension of the resection till the
T2-weighted magnetic resonance imaging (MRI) zone were confirmed by early contrast
MRI (within 24/48 h after surgery), comparing pre- and post-operative contrast-enhanced
images. Paired GBM and PT tissue samples were obtained from the enhanced lesion
without areas of necrosis (GBM) and from the white matter at a distance of <1 cm from the
macroscopic tumor border (PT tissue). None of the patients had received radiotherapy or
chemotherapy before surgical resection. Thirty-five to forty days after surgery, all patients
underwent irradiation and chemotherapy was performed according to the literature [2].
The histological diagnosis was evaluated for sections stained with hematoxylin-eosin
according to the 2007 World Health Organization (WHO) classification guidelines [1]. Neo-
plastic cells were identified by large hyperchromatic and irregular nuclei, while reactive
astrocytes were recognized by the dendritic morphology of their abundant eosinophilic
cytoplasm and large, eccentric nuclei, according to Hoelzinger et al. [49]. The survival
period was defined as the time from the date of surgery to the date of death.
4.2. Immunohistochemistry and Stereological Analysis
Five-micrometer-thick sections of 10% formalin-fixed, paraffin-embedded tissues from
tumor and PT samples were used for immunohistochemistry analysis. Before proceeding
with immunolabeling, sections were deparaffinized in xylene and treated with 0.3% hydro-
gen peroxide in methanol for 20 min to block endogenous peroxidase activity. The sections
were washed in phosphate-buffered saline and then incubated with primary antibodies
(dilution 1:50) overnight, followed by incubation with the appropriate secondary antibod-
ies. The substrate chromogen, 3.30-diaminobenzidine (DAB), enabled visualization of the
nuclear expression of MGMT via a brown precipitate. Hematoxylin (blue) counterstaining
enabled the visualization of the cell nuclei. Omission of the primary antibody served as
a negative control. Immunostaining for MGMT, BCRP1, and A2B5 was performed using
the standard protocol on automated staining Dako Autostainer PlusLink (Dako, Glostrup,
Denmark) until antigen unmasking. Target retrieval solution (pH 9) was used for antigen
unmasking on the Dako PT Link Autostainer. Then a manual staining method was used to
reveal protein expression. Hydrogen peroxide (0.3%) was applied to block endogenous
peroxide activity. A block of non-specific staining (Super Block, UCS Diagnostic S.r.l.,
Morlupo, Italy) was followed by incubation with primary antibodies, anti-MGMT (1:200),
anti-BCRP1 (1:100), and anti-A2B5 (1:100), overnight at 4 ◦C. Subsequently, the sections
were incubated with an HRP/Fab polymer conjugate (SuperPicTure Polymer DetectionKit,
Invitrogen, Camarillo, CA, USA). The reaction was visualized with 3,3′-diaminobenzidine
(Peroxidase DAB substrate kit, Vector Laboratories Inc., Burlingame, CA, USA), resulting
in the expected brown-colored signal. Finally, all the sections were counterstained with
Mayer’s hematoxylin and dehydrated in ethanol before mounting. No staining was de-
tected in negative control sections in which the primary antibody had been omitted. For
accurate quantification of immunopositive cells, an unbiased stereological technique by
means of the Stereo Investigator system was employed (Stereo Investigator software, v 9.14
2010, MicroBrightField Europe, Magdeburg, Germany), as previously reported [47,50–52].
A stack of MAC 6000 controller modules (Ludl Electronic Products, Ltd., Hawthorne, NY,
USA) was configured to interface a light microscope (Nikon Eclipse 80i, Nikon Corporation,
Tokyo, Japan) with a motorized stage and a color digital camera (MicroBrightField) with
a PC workstation. First, each region of interest (ROI) was outlined at low magnification
(×100) and then scanned using the Meander scan function. All immunopositive and im-
munonegative cells within the ROI were counted at x400 magnification. The cell density
was determined by dividing the number of immunopositive or immunonegative cells by
the area of the ROI (cells/mm2). Data expressed as a percentage of positive cells were used
for statistical analysis. It is worth mentioning that due to the limited amount of peritumoral
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tissue available in some cases, only 50 of the 55 patients were analyzed for MGMT, BCRP1,
and A2B5.
4.3. Statistical Analysis
Patient variables were collected in Excel sheet 2011 for Mac Rev. 14.7.7 and then
analyzed with Stata/IC 14.2 for Mac software Rev. 29 January 2018 (StataCorp Lakeway,
College Station, TX, USA). Kaplan–Meier life-table analysis was performed for actuarial
survival analysis. Continuous variables were reported as the mean and standard deviation
or median (range), and categoric variables were reported as frequencies (%). All variables,
including demographic ones, were normally distributed and statistically significant with
Shapiro–Wilk and Shapiro–Francia tests for normality, except for the KPS variable. The
survival time was considered the end point, the nonparametric variables were compared
with the Pearson χ2 test, and all the remaining variables were compared by parametric tests
such as analysis of variance and the τ-test. Univariate analyses (nonparametric log-rank test
of equality across strata and Cox proportional hazard regression as a semiparametric model)
were performed to identify proportionality between groups and to test associations between
survival and the variables of interest, which were useful in designing the model of the
survival curve. Variables with univariate p-values of 0.1 were considered in multivariable
models, which were also adjusted for age and gender. To facilitate the interpretation
of hazard and odds ratios, continuous variables were dichotomized in the final models,
based on the cutoff point as determined by receiver operating characteristic (ROC) analysis.
Stepwise backward elimination (SBE) is a procedure that helps select important factors
and eliminate weak factors; therefore, multivariate logistic regression (MVREG) and SBE
procedures were performed to develop the final models. A p-value of 0.05 was considered
statistically significant for all analyses. The long-term survival analyses were calculated
from the date of the histochemical diagnosis.
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